×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AKTS – aktis oncology, inc. - common stock (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AKTS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/16
08:00 am
akts
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
Low
Report
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
3/31
08:02 am
akts
Aktis Oncology (AKTS) had its price target raised by HC Wainwright from $30.00 to $33.00. They now have a "buy" rating on the stock.
Medium
Report
Aktis Oncology (AKTS) had its price target raised by HC Wainwright from $30.00 to $33.00. They now have a "buy" rating on the stock.
3/30
04:01 pm
akts
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
Medium
Report
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
3/9
08:03 am
akts
Aktis Oncology (AKTS) is now covered by HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.
Medium
Report
Aktis Oncology (AKTS) is now covered by HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.
2/24
04:05 pm
akts
Aktis Oncology to Present at Upcoming March Investor Conferences
Low
Report
Aktis Oncology to Present at Upcoming March Investor Conferences
2/24
08:00 am
akts
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
High
Report
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
2/3
07:00 am
akts
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Medium
Report
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
2/3
07:00 am
akts
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $31.00 price target on the stock.
Medium
Report
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $31.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/7
Akoustis Technologies to Attend the 4th Annual Oppenheimer Emerging Growth Conference on May 14, 2019
20.3%
7/10 Akoustis Expects June Quarter Revenue at Upper End of Previous Guidance 18.0%
4/21 Form 8-K Akoustis Technologies, For: Apr 17 15.8%
12/11 Form 424B5 Akoustis Technologies, 14.2%
4/3 Form 4 Akoustis Technologies, For: Apr 01 Filed by: Shealy Jeffrey B. 11.2%
4/8 Akoustis Announces First 5G Network Infrastructure Design Win with Tier-1 OEM 10.6%
8/26 Akoustis Technologies Inc (NASDAQ: AKTS) was given a new $7.00 price target on by analysts at Northland Securities. They now have a "buy" rating on the stock. 9.7%
11/8 Akoustis Ships 60,000 Pre-Production 5.6 GHz WiFi Filters to Leading RF Customer 9.2%
5/10 Q3/2019 3/31/2019 EPS -0.310 ZacksConsensus N/A ActVsEst N/A - N/A 9.1%
1/6 Form 4 Akoustis Technologies, For: Jan 06 Filed by: Denbaars Steven 6.9%
7/10 Akoustis Expects June Quarter Revenue at Upper End of Previous Guidance 18.0%
4/21 Form 8-K Akoustis Technologies, For: Apr 17 15.8%
12/11 Form 424B5 Akoustis Technologies, 14.2%
4/3 Form 4 Akoustis Technologies, For: Apr 01 Filed by: Shealy Jeffrey B. 11.2%
4/8 Akoustis Announces First 5G Network Infrastructure Design Win with Tier-1 OEM 10.6%
8/26 Akoustis Technologies Inc (NASDAQ: AKTS) was given a new $7.00 price target on by analysts at Northland Securities. They now have a "buy" rating on the stock. 9.7%
11/8 Akoustis Ships 60,000 Pre-Production 5.6 GHz WiFi Filters to Leading RF Customer 9.2%
5/10 Q3/2019 3/31/2019 EPS -0.310 ZacksConsensus N/A ActVsEst N/A - N/A 9.1%
1/6 Form 4 Akoustis Technologies, For: Jan 06 Filed by: Denbaars Steven 6.9%
TOP News Decliners
2/3
Akoustis Announces First Commercial Volume Order for 5G Infrastructure RF Filters
-10.0%
3/17 Form 4 Akoustis Technologies, For: Mar 13 Filed by: Houlden Rohan -8.3%
11/6 Form 4 Akoustis Technologies, For: Nov 04 Filed by: NEAL JERRY D -6.3%
12/17 Akoustis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares -6.2%
4/15 Form 4 Akoustis Technologies, For: Apr 13 Filed by: McMahon Jeffrey -5.9%
5/17 Form 4 Akoustis Technologies, For: May 17 Filed by: Aichele David -4.7%
11/5 Akoustis Technologies Inc (NASDAQ: AKTS) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.5%
11/6 Akoustis to Webcast Investor Update Call November 8th at 8:00 a.m. EDT -4.4%
7/10 Form 4 Akoustis Technologies, For: Jul 08 Filed by: Denbaars Steven -4.1%
11/13 Akoustis Technologies Inc (NASDAQ: AKTS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -3.7%
3/17 Form 4 Akoustis Technologies, For: Mar 13 Filed by: Houlden Rohan -8.3%
11/6 Form 4 Akoustis Technologies, For: Nov 04 Filed by: NEAL JERRY D -6.3%
12/17 Akoustis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares -6.2%
4/15 Form 4 Akoustis Technologies, For: Apr 13 Filed by: McMahon Jeffrey -5.9%
5/17 Form 4 Akoustis Technologies, For: May 17 Filed by: Aichele David -4.7%
11/5 Akoustis Technologies Inc (NASDAQ: AKTS) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.5%
11/6 Akoustis to Webcast Investor Update Call November 8th at 8:00 a.m. EDT -4.4%
7/10 Form 4 Akoustis Technologies, For: Jul 08 Filed by: Denbaars Steven -4.1%
11/13 Akoustis Technologies Inc (NASDAQ: AKTS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -3.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: